CLINICAL TRIALS PROFILE FOR MEBENDAZOLE

All Clinical Trials for mebendazole

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01314937 ↗	The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas	Completed	Asociacion Civil Selva Amazonica	Phase 4	2011-09-01	Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
NCT01314937 ↗	The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas	Completed	Canadian Institutes of Health Research (CIHR)	Phase 4	2011-09-01	Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
NCT01314937 ↗	The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas	Completed	McGill University	Phase 4	2011-09-01	Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
NCT01173562 ↗	A Safety Study of Mebendazole in Children 2 to 10 Years of Age	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2010-02-01	The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.
NCT01050452 ↗	Safety and Efficacy of Drug Combinations Against Trichuris Trichiura	Completed	DBL -Institute for Health Research and Development	N/A	2007-10-01	This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.
NCT00116493 ↗	Severe Anemia Treatment Trials, Pakistan	Completed	Aga Khan University	Phase 3	2004-04-01	The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan.
NCT00116493 ↗	Severe Anemia Treatment Trials, Pakistan	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	2004-04-01	The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan.

Clinical Trial Conditions for mebendazole

Condition Name

Condition Name for mebendazole
Intervention	Trials
Helminthiasis	3
Anaplastic Astrocytoma	2
Hookworm Infections	2
Anemia	2

Condition MeSH

Condition MeSH for mebendazole
Intervention	Trials
Helminthiasis	7
Infection	6
Infections	6
Hookworm Infections	5

Clinical Trial Locations for mebendazole

Trials by Country

+

−

Trials by Country for mebendazole
Location	Trials
United States	4
Tanzania	4
Ethiopia	3
Egypt	2
Uganda	2

Trials by US State

+

−

Trials by US State for mebendazole
Location	Trials
Maryland	2
Florida	1
New York	1

Clinical Trial Progress for mebendazole

Clinical Trial Phase

Clinical Trial Phase for mebendazole
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for mebendazole
Clinical Trial Phase	Trials
Completed	18
Recruiting	5
Unknown status	2

Clinical Trial Sponsors for mebendazole

Sponsor Name

Sponsor Name for mebendazole
Sponsor	Trials
University Ghent	3
Bill and Melinda Gates Foundation	3
Swiss Tropical & Public Health Institute	3

Sponsor Type

Sponsor Type for mebendazole
Sponsor	Trials
Other	81
Industry	9
NIH	1

Mebendazole: Clinical Trials, Market Analysis, and Projections

Introduction to Mebendazole

Mebendazole, a benzimidazole carbamate, is a widely used antiparasitic drug approved by the US Food and Drug Administration (FDA) for treating various parasitic infections. Recently, it has garnered significant attention for its potential in treating cancer, particularly brain tumors and other malignancies.

Clinical Trials Update

Current and Completed Trials

Several clinical trials are underway or have been completed to evaluate the efficacy and safety of mebendazole in treating various types of cancers.

• Phase I Study of Mebendazole for Pediatric Gliomas: This trial, conducted by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, is recruiting patients to assess the safety and efficacy of mebendazole in treating recurrent or progressive pediatric brain tumors, including medulloblastoma, astrocytoma, and glioblastoma. The trial is expected to complete in April 2024[1][4].

• Other Ongoing Research: Preclinical studies have shown promising results with mebendazole in treating glioblastoma multiforme (GBM) and other gliomas. These studies indicate that mebendazole can extend mean survival in mouse glioma models by disrupting microtubule formation and reducing tubulin polymerization[3].

Mechanism of Action in Cancer

Mebendazole's mechanism of action in cancer involves disrupting microtubule formation, which is crucial for cell division. In GBM cell lines, mebendazole has shown cytotoxicity with half-maximal inhibitory concentrations ranging from 0.1 to 0.3 µM. This disruption leads to reduced cell proliferation and increased apoptosis in cancer cells[3].

Market Analysis

Global Market Size and Growth

The global mebendazole market has been growing steadily, driven by several key factors.

• Current Market Size: As of 2023, the mebendazole market was valued at USD 231.8 million[5].
• Projected Growth: The market is expected to reach USD 470.2 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 8.2% from 2024 to 2031[5].

Drivers of Market Growth

Several factors are driving the growth of the mebendazole market:

• Increasing Prevalence of Parasitic Infections: The rising prevalence of parasitic infections globally necessitates efficient treatment options, thereby increasing the demand for mebendazole[5].
• Deworming Programs: Government initiatives and widespread implementation of deworming programs in communities and schools have significantly increased market demand[5].
• Technological Advancements: Improvements in drug formulation and delivery technologies have enhanced the effectiveness and convenience of mebendazole, attracting more consumers[5].
• Expanding Healthcare Infrastructure: Growing healthcare spending and expanding access to healthcare services in emerging nations are also fueling market growth[5].

Competitive Dynamics

The global mebendazole market is characterized by a competitive landscape involving various key players. The market share and revenue of these companies are analyzed in detailed reports, which also include a Porter’s Five Forces analysis to understand the bargaining power of buyers and suppliers, the threat of new entrants, the threat of substitutes, and the degree of competition[2][5].

Market Projections

Revenue Growth

The mebendazole market is projected to experience significant revenue growth. From 2019 to 2025, the market is expected to grow from $103.1 million to $129.4 million, registering a CAGR of 5.8%[2].

Regional and Segment Analysis

The market is segmented by key players, product types, applications, and regions. These segments help in understanding the market dynamics and identifying opportunities and trends. The report provides a comprehensive analysis of the global market share, growth rate, and investment strategies for the mebendazole market[2][5].

Key Takeaways

• Clinical Trials: Mebendazole is being investigated in clinical trials for its potential in treating pediatric gliomas and other brain tumors, with promising preclinical results.
• Market Growth: The global mebendazole market is expected to grow significantly, driven by the increasing prevalence of parasitic infections, deworming programs, technological advancements, and expanding healthcare infrastructure.
• Revenue Projections: The market is projected to reach $129.4 million by 2025 and $470.2 million by 2031, with a CAGR of 5.8% and 8.2%, respectively.
• Competitive Landscape: The market is competitive, with various key players and a detailed analysis of market dynamics and competitive forces.

FAQs

What is the current status of mebendazole in clinical trials for cancer treatment?

Mebendazole is currently in Phase I clinical trials for the treatment of pediatric gliomas and has shown promising results in preclinical studies for treating glioblastoma multiforme (GBM) and other gliomas[1][3].

How is the global mebendazole market expected to grow?

The global mebendazole market is expected to grow from $103.1 million in 2019 to $129.4 million by 2025, and further to $470.2 million by 2031, with CAGRs of 5.8% and 8.2%, respectively[2][5].

What are the key drivers of the mebendazole market growth?

The key drivers include the increasing prevalence of parasitic infections, government-initiated deworming programs, technological advancements in drug formulation, and expanding healthcare infrastructure in emerging nations[5].

How does mebendazole work in treating cancer?

Mebendazole disrupts microtubule formation in cancer cells, leading to reduced cell proliferation and increased apoptosis. This mechanism is particularly effective in treating glioblastoma multiforme (GBM) and other gliomas[3].

Is mebendazole approved by regulatory authorities for cancer treatment?

Mebendazole is approved by the FDA for treating parasitic infections but is not yet approved for cancer treatment. However, it is being investigated in clinical trials for its potential in oncology[3].

What are the potential side effects of mebendazole in cancer treatment?

While mebendazole has a long track record of safe use in humans for parasitic infections, its side effects in cancer treatment are being closely monitored in ongoing clinical trials. Common side effects of mebendazole include gastrointestinal issues, but specific side effects in cancer treatment may vary and are under investigation[1][3].

Sources

1. DIPG Registry: Clinical Trials - DIPG Registry.
2. OpenPR: Mebendazole Market: Competitive Dynamics & Global Outlook 2025.
3. Neuro-Oncology: Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
4. LARVOL VERI: News - mebendazole.
5. Market Research Intellect: Mebendazole Market Size and Projections.